Classifying the mechanisms of antibiotic failure has led to the development of new treatment strategies for killing bacteria. Among the currently described mechanismswhich include resistance, persistence and tolerancewe propose defiance as a form of antibiotic failure specific to prodrugs. As a prototypic bacteria-activated prodrug, we construct cationic antimicrobial 5 peptides (AMP), which are charge neutralized until activated by a bacterial protease. Despite prodrug treatment eliminating the vast majority of bacteria populations, we observe defiant phenotypes that survive exposure to identical drug concentrations and durations. Using a multirate kinetic feedback model, we show that bacteria spontaneously switch from susceptibility to defiance under disease-related physiological conditions (e.g., hyperthermia, downregulated 10 protease expression). From this model, we derive a dimensionless quantity (Bacterial Advantage Heuristic, BAH)representing the competing rates between bacterial proliferation and prodrug activationthat perfectly classifies bacteria as defiant or susceptible across a broad range of conditions. By recognizing that the switch from susceptibility to bacterial defiance under prodrug treatment behaves analogously to electronic transistors, we construct biological logic gates (e.g., 15 AND, OR, NOT, etc.) to allow assembly of an integrated 3-bit autonomous circuit that universally kills defiant bacteria under all possible combinations of BAH values. Here, we study a form of bacterial resistance specific to prodrugs, which reveals universal treatments strategies that can be implemented with biological circuits. 20 25
INTRODUCTION
The rise of multidrug-resistant bacteria coupled with the lack of newly developed antibiotics has created a serious public health threat 1, 2 . Understanding the causes of antibiotic failure improves the development of new drugs and informs clinical treatment strategies [3] [4] [5] . These failure mechanisms are broadly classified into three distinct categories (i.e., resistance, 5 persistence, and tolerance), which are characterized by the change in drug concentration and exposure time required to kill the bacteria 6 . For example, resistance is characterized by genetic mutations which result in bacteria requiring significantly higher concentrations of antibiotic (minimum inhibitory concentration, MIC) to be lethal. By contrast, bacteria exhibiting tolerance or persistence require increased drug exposure time (minimum duration for killing, MDK), with the 10 latter exhibiting a biphasic killing profile. Further, bacteria populations become tolerant through environmental conditions or genetic mutations, whereas persistence is an actively maintained, non-heritable state exhibited by a subpopulation of bacteria. Discriminating between these survival strategies employed by bacteria is crucial for the development of new drugs and clinical treatment decisions 6 . 15
Antibiotic success is markedly improved by proper drug titration, as overdosing leads to off-target toxicity and underdosing increases the likelihood of pathogens developing resistance 7, 8 . However, ideal drug doses are difficult to achieve over the course of treatment because infection burden changes dynamically over time, creating a moving target [7] [8] [9] . Prodrugs, which represent 10% of all FDA-approved drugs in the last decade, are a promising solution because they are 20 automatically titrated by a disease-related activation mechanism and reduce the risk of off-target effects 10 . Prodrugs, such as ganciclovir 11 and sultamicillin 12 , are administered as a biologically inactive form and are enzymatically or chemically activated by the diseased cells or pathogens.
Here, we create self-titrating prodrugs using cationic antimicrobial peptides (AMP), which evolved as a part of innate immunity and display broad-spectrum and prokaryote-specific antimicrobial 25 properties 13 . Cationic AMPs act by disrupting bacterial membranes and inducing inflammatory responses 14 , but suffer from off-target effects (i.e., toxicity) and low stability in vivo 15, 16 . Our AMP prodrugs are activated directly by proteases, a multifunctional class of enzymes that are responsible for regulating important health processes, such as immunity and blood homeostasis, and are major drivers of disease, including cancer and sepsis [17] [18] [19] [20] [21] [22] . We chose to target bacterial 5 proteases directly, which are a major cause of virulence 23, 24 during infections and important targets for developing antibiotics 25 . Of these proteases, outer membrane protease T (OmpT), is a membrane-bound bacterial protein that is widely conserved across gram-negative bacteria of the Enterobacteriaceae family and recognizes a variety of targets that contribute to virulence (e.g., plasminogen) [26] [27] [28] . In this work, we design cationic AMPs that are locked by charge complexation 10 with anionic peptides and connected with a protease-cleavable linker substrate 29, 30 . We create a peptide linker recognized by E. coli protease OmpT, such that increasing concentrations of bacteria yield higher concentrations of free drug (Fig. 1A) .
While this formulation eliminates the majority of bacteria, we observe bacteria populations that we named defiant, which proliferate in the presence of active drug by consistently outpacing 15 prodrug activation at all stages of growth (i.e., log phase, stationary phase). To understand the mechanism by which bacteria become resistant to prodrugs, we built a system of coupled ODEs that model the dynamics of the bacteria-prodrug competition. We use this model to derive the dimensionless quantitythe Bacterial Advantage Heuristic (B.A.H.)which predicts whether bacteria will become defiant under a broad range of conditions. At low BAH values, bacteria are 20 susceptible to elimination, but after a critical threshold the bacteria switch to a state of defiance, in which the bacteria proliferate in the presence of activated drug ( Fig. 1B) . To combat this, we design biological circuits that universally treat all conditions (BAH values) by recognizing that prodrugs behave analogously to transistors: above a critical BAH threshold (i.e., gate voltage), bacteria (i.e., input current) pass through the prodrug and exhibit defiance. Under this definition 25 of a bit, defiant bacteria represent the 1-state and dead bacteria represent the 0-state. We use this framework to build digital logic gates with prodrug transistors, which operate on multiple BAH values and output a binary bacteria population (i.e., living or dead). We arrange multiple AND and NOT gates to construct a circuit that outputs 0 (i.e., dead bacteria) under all eight possible combinations of three input BAH values (Fig. 1D) . These quantitative mechanistic insights will 5 better inform future drug design and treatment protocols leading to antibiotic success. 
RESULTS & DISCUSSION

Creating a bacterial protease-activated prodrug 5
To create a bacteria-activated prodrug, we developed an antimicrobial peptide (AMP) that is activated by protease activity. This formulation consisted of a cationic AMP (polyarginine) in charge complexation with anionic peptide locks (polyglutamic acid) to create an inactive form of the AMP 29 . The drug (polyarginine) and lock (polyglutamic acid) were connected with a linker peptide (RRSRRV) that is unlocked by a bacterial protease (OmpT) upon proteolytic cleavage, 10 creating a precise mechanism for self-titration ( Fig. 2A) . To demonstrate the specificity of OmpT for the chosen linker peptide sequence, we synthesized a fluorogenic peptide containing a fluorescence-quencher pair 27 
and detected OmpT activity in samples incubated with recombinant
OmpT or live E. coli culture. Further, we demonstrated the ability to turn off OmpT activity with the serine protease inhibitor, Aprotinin, which exhibits inhibitory effects in the micromolar range 26 15 ( Fig. 2B ). Using this substrate, we confirmed that the proteolytic cleavage of this substrate linker also occurred when docked on the drug-lock complex, which presents a different conformational state of the peptide substrate ( Fig. 2C) . To determine the MIC of the unlocked drug, we showed that bacteria dosed with free drug show no growth in comparison to bacteria alone ( Fig. 2D, E) .
Dosing locked prodrug at this concentration, we used an orthogonal protease (Tobacco Etch Virus 20
Protease) substrate pair to show the drug is only activated to kill bacteria in the presence of the correct target protease. We then used the prodrug locked with the OmpT substrate to show that the drug is only activated in the presence of bacterial protease activity. In the presence of the prodrug, all bacteria were eliminated whereas in the presence of the prodrug and the OmpT inhibitor, Aprotinin, bacteria proliferated at the same rate as the bacteria alone control ( Fig. 2D , Table S1 ). To summarize, we designed charge neutralized cationic peptides that behave as prodrugs when activated by the bacterial protease, OmpT. 
Bacteria-prodrug kinetic model
The bacteria-activated prodrug leveraged protease activity to enable auto titration according to a rate constant (i.e., activated drug concentration per time), which is a function of system parameters such as enzymatic efficiency (kcat/Km) and bacterial growth rate (r). To quantitatively understand how the rate of prodrug activation competes with the number of living 10 bacteria, we built a mathematical model using a system of nonlinear ordinary differential equations (ODE). In this model, the prodrugs create a negative feedback loop, where bacteria activate prodrugs, which in turn inhibit bacterial growth ( Fig. 3A) . We modeled the growth of the bacteria population, B, with a standard logistic growth model 31 , where Bmax determines the bacterial carrying capacity (maximum concentration of bacteria) and the growth rate, r, determines the 15 speed at which the population approaches Bmax. The decay of the bacteria population is a function of the concentration of unlocked drug, U, and the amount of drug needed to kill bacteria per unit time, a (Table S2, Equation 1.1).
The drug is unlocked by enzymatic activity, so we modeled the decay of the available locked drug, 20 L, with standard Michaelis-Menten kinetics where the catalytic rate of the reaction and the halfmaximal substrate concentration are determined by kcat and Km, respectively (Equation 1.2). We defined one bacterium, with ~ 2.5 × 10 3 OmpT proteases per cell 32 , as equivalent to one effective enzyme to reflect the valency of protease active sites on each bacterial membrane.
The conversion from locked to unlocked drug, U, is conserved, so the decay of locked drug directly translates to the growth of unlocked drug. The unlocked drug decays, a * , due to aggregation with 5 dead bacteria membranes, for which we used published values 33 (Equation 1.3) .
To fit this model to our data, we measured the parameters included in the model, including drug cytotoxicity (e.g., EC50, a), enzymatic efficiency (e.g., kcat, Km), and bacterial growth rate (r) ( Fig.  10 S1A-C). Using these values (Table S2) , the model showed that after a period of initial bacterial growth, the lagging drug population ultimately eliminated the bacteria. While the initial reservoir of locked drug concentration was ~200 µM, the unlocked drug never rose above 5 µM ( Fig. S1D) , revealing that this system maintains the minimal drug concentration required to kill the infection. To apply this model to a broad range of prodrugs, we developed a general form of the prodrug-15 disease target model based on well-established pharmacokinetic parameters ( Fig. S2) .
Predicting bacterial defiance with a dimensionless constant
While it is advantageous for prodrugs to minimize the concentration of active drug, we show that this enables defiant populations of bacteria to appear under certain circumstances. We 20 hypothesized that a critical relationship between the system parameters (e.g., kcat/Km, r, etc.) determines whether bacteria become defiant. Using Buckingham Pi theorem, we derived a dimensionless quantity representing the balance between growth rate (r) and enzymatic turnover (kcat/Km), which we define as the Bacterial Advantage Heuristic increased because the bacteria were more likely to multiply before being killed by an activated drug. Conversely, the BAH decreased as bacterial enzyme activity (kcat/Km) increased, because the bacteria were more likely to unlock a larger quantity of drug before dying.
To find the critical BAH threshold that determined defiance, we set up nine different environmental conditions, each with a unique combination of kcat/Km and r values, which we 10 controlled with ambient temperature, broth concentration and protease inhibitors. We incubated bacteria with the previously developed fluorophore-quencher probe (Fig. 2B) to monitor bacterial protease activity over time in each of the nine conditions. To quantify r, kcat/Km and BAH, we fit a simplified model of logistic bacteria growth and enzymatic turnover in a system with no prodrug ( Fig. S3A, Table S2 , Equations S1.7, S1.8). To measure the outcome of bacteria populations 15 exposed to the prodrug, we set up the same nine environmental conditions with the addition of the prodrug. We found experimentally that the final bacteria population (i.e., steady-state value) was binary: either 0 or Bmax (Fig. 3B) . Therefore, a population of bacteria in the presence of a prodrug will converge to either susceptibility (death) or defiance (survival), which was also confirmed analytically ( Fig. 3C , Equations S1.9, 1.10). To validate our model, we made serial 20 CFU measurements, which closely matched the bacterial growth predicted by our simulations in each of the nine conditions ( Fig. 3D, Fig. S3B , Table S3 ). To computationally predict the critical BAH threshold, we simulated 10 4 unique BAHs by varying r and kcat/Km across four orders of magnitude and comparing to the simulated outcome (BAHcrit = 3.261). We confirmed this result experimentally by plotting live/dead results versus BAH from each of the nine conditions, which revealed a sharp step function near the same critical value (BAHcrit = 3.17-3.44) ( Fig. 3E) . When using the BAH as a binary classifier of this system, we perfectly predicted the onset of bacterial defiance under a set of 13 unique environmental conditions ( Fig. 3F, G) . Further, we demonstrated the ability to switch defiant bacteria to a state of susceptibility by changing the 5 amino acid sequence of the peptide linker, increasing kcat/Km (Fig. S4) . Taken together, these results show that insights gained from a non-dimensional value can improve prodrug success using design principles guided by a dimensionless quantity, BAH. 5
Building logic gates with prodrug transistors
We sought to leverage the binary properties of these prodrugs to design a biocircuit capable of universally treating bacterial defiance. We accomplished this by recognizing that certain prodrugs behave analogously to electronic transistors. Transistors allow input current (Iin) to pass (Iout) when the gate voltage (G) is above a defined threshold; similarly, prodrugs allow input bacteria (Bin) to 10 survive (Bout) when the BAH is above a critical value (Fig. 4A) . Within computers, transistors are arranged in small circuits to create digital logic gates, which are in turn combined to form larger circuits that perform sophisticated tasks. We sought to emulate this hierarchical structure and leverage the transistor-like behavior of prodrugs to create a circuit capable of combatting bacterial defiance, which required transistors as well as NOT gates. In contrast to a transistor, a NOT gate 15 kills bacteria when BAH = 1, and allows bacteria to survive when BAH = 0 ( Fig. 4B) . To create a NOT gate, we used heat triggered liposomes 34 that release drugs when heated above 37C (Fig.   S5 ). When exposed to temperatures above 37C, which correspond to BAH = 1, the liposomes released the drugs, killing bacteria, whereas lower temperatures (i.e., BAH = 0) allowed bacteria to survive (Fig. 4B) . These results demonstrate the function of prodrugs as bacterial transistors 20 or NOT gates, which can be arranged in simple circuits to create digital logic gates. 
Combatting bacterial defiance with an autonomous, universal circuit
The goal of programmable medicine is to design autonomous biological circuits capable of diagnosing and treating disease. We sought to leverage the transistor-like behavior of prodrugs to combat the problem of bacterial defiance. We proposed a set of three environmental inputs 15 described by BAH values (i.e., BAHA, BAHB, and BAHC), which were each controlled with different system parameters (i.e., media concentration, temperature, and substrate sequence). We computationally generated 32 candidate circuits that produce the output 0 under all eight combinations of input conditions and only use AND, OR, or NOT gates. We chose a simple circuit, which uses 3 AND gates and 1 NOT gate (Fig. 5A, B) . To create AND gates with prodrugs, we mirrored the arrangement of electronic transistors by placing two prodrugs, each with an associated BAH input (i.e., BAHA and BAHB) in series by sequentially dosing the bacteria (Fig.  5   5C) . For this example, we used two drugs with different substrate specificities, where the substrate with high kcat/Km corresponds to BAH = 0 and the substrate with low kcat/Km corresponds to BAH = 1. When exposed to all four possible inputs (i.e., 00, 01, 10, and 11), bacteria only survived the 11 condition, creating an AND gate function (Fig. 5C) . Whereas the AND gate was created with prodrugs in series, we recapitulated the OR gate by arranging two prodrugs in 10 parallel. Using this circuit, bacteria survived in any case where at least one input BAH = 1, creating an OR gate function (Fig. 5D) . To create the universal circuit (Fig. 3A) , we mixed a cocktail of 3 AND gates and 1 NOT gate and applied this circuit to all eight possible input conditions. Whereas a single prodrug only eliminated bacteria in about half of the input cases ( Fig. 5E) , our circuit autonomously eliminated bacteria in all possible combinations (Fig. 5F) . Here, we augment 15 prodrugs with the capacity to respond to a broad range of physiological conditions. In addition to self-dosing, programmable prodrugs have the potential to universally respond to different biological states. 
CONCLUSION
While these findings complement existing knowledge about bacterial mechanisms that cause antibiotic failure, prodrugs introduce a unique element: the competition between bacterial growth and prodrug activation. To understand this behavior, we establish bacterial defiance as a form of antibiotic failure which allows bacteria to proliferate while activating prodrugs. To study 5 bacterial defiance, we created an OmpT-activatable AMP prodrug with the ability to localize its activity to E. coli membranes and elicit precise titration. This formulation can be applied to other diseases by designing a peptide linker specific to a disease-related protease. We established a mathematical framework for determining the mechanism of defiance for bacteria and general diseases. Under this framework, measurable system parameters determine whether bacteria will 10 become defiant in the presence of a particular prodrug. Our model reveals that there are many parameters, including drug half-life and temperature, that can be controlled to improve prodrug efficacy. In addition to the environmental conditions studied in this work, there are established genetic mutations in E. coli capable of causing defiance. For example, mutations resulting in partial reduction or total loss of OmpT activity 35, 36 as well as changes in growth rate 37 have been 15 identified in E. coli.
The proposed framework for characterizing defiance will enable more conscious engineering of prodrugs and provide strategies for combatting antibiotic failure. By creating an autonomous circuit that kills bacteria in a variety of physiological conditions, we demonstrate an ideal template for administering prodrugs in the context of defiant populations of bacteria. 20
Prodrugs are already a promising strategy for combatting antibiotic failure, because they are selfdosing and reduce off-target effects 10 . By engineering prodrugs treatments with logically controlled circuits, future treatments will also be able to universally respond to different physiological states. Under the paradigm of programmable medicine, augmented prodrugs may prove to combat the growing problem of antibiotic resistance. 25 Table S1 for more information. Bacteria were grown to a concentration of 10 9 CFU/mL before being used for experiments. Concentration was estimated by measuring the OD600 of the bacterial suspension, and assuming an OD600 of 1.000 corresponds to a concentration of 8 x 10 8 CFU/mL. 20
Bacterial cell viability was measured by making eight 10-fold serial dilutions, and plating three 10 uL spots on an LB agar plate. Plates were incubated overnight at 37C, and CFUs were counted. Untreated bacteria CFU counts served as control for 0% cytotoxicity, and bacteria + IPA (or 0 countable CFUs) served as control for 100% cytotoxicity. 25 Liposome Preparation DPPC and MPPC were purchased from Avanti Polar Lipics, inc. The heat-triggered NOT gate formulation was composed of DPPC:MPPC at the molar ratio 9:1, and were evaporated in cholorform to produce a lipid film. Films were rehydrated in 100% water containing 100 mg/mL ampicillin and were sonicated for 20 minutes. Lipid formulations were then purified using a PD- 10 30 desalting column (GE Healthcare) and size was measured via dynamic light scattering (DLS, Malvern).
Computational model
The ODE modelling and solutions were performed in MATLAB 2016b. Code can be found in 35 supplementary information.
Statistical Analysis
Statistical analysis was performed using statistical packages included in GraphPad Prism 6. To assess the significance of increase in signal due to protease cleavage, we used a two-way 40 ANOVA (without repeated measures) followed by Sidak's multiple comparisons test. A one-way ANOVA followed by Dunnett's multiple comparisons test was used to compare experimental means to cells only control bacterial viability assays. Two-way ANOVA followed by Sidak's multiple comparisons test used to compare experimental means to control for bacterial cytotoxicity at multiple starting concentrations. 45
SUPPLEMENTARY INFORMATION, FIGURES, AND TABLES
Measuring kinetic parameters for the ODE model
To measure drug cytotoxicity, we quantified the percent of viable bacteria when exposed to unlocked AMP drug doses ranging from nanomolar to millimolar concentrations and observed a 5 spike in cytotoxicity in the micromolar range (Fig. S1A) . To calculate bacterial growth rate constants, we incubated bacteria in broth or water at 37C and measured OD600 over the course of 8 hours, revealing a higher growth rate in broth consistent with published values 31, 37 (3.0 > 0.1 h -1 ) (Fig. S1B) . To quantify enzymatic velocity, we measured proteolytic velocity (moles L -1 s -1 ) under substrate concentrations ranging from 0-200 uM and fit the Michaelis-Menten equations 10 to this data to calculate kcat and Km (Fig. S1C ). Using these measured parameters (Table S2) , we generated kinetic curves for bacteria number and drug concentration over time. The model showed that after a period of initial bacterial growth, the lagging drug population eliminated the infection burden. While the initial reservoir of locked drug concentration was ~200 µM, the unlocked drug never rose above 5 µM (Fig. S1D) , revealing that this system maintains the minimal 15 drug concentration required to kill the infection. A generalized model of disease-triggered prodrugs.
To apply the concept of bacterial defiance to a broad range of prodrugs, we developed a general 10 form of the prodrug-disease target model. This model did not depend on the mechanism of action ( Fig. S2A) and raised each variable to an arbitrary power to allow for both linear and non-linear processes. In this system, we described a disease (D) which converts a prodrug (P) into an active form (A) by an arbitrary mechanism (Equations S1.1-S1.3):
We defined four generalized parameters: disease expansion rate (a), drug efficiency (b), drug activation rate (c), and drug decay (i.e., metabolism and excretion, d), which are well-established pharmacokinetic parameters for prodrugs. We defined a boundary condition based on the 5 constraint that total drug concentration (i.e., prodrug + active drug) is always decreasing and is therefore less than the initial prodrug concentration, which must hold true for any time, t (Equation S1.4). By substituting the steady state values of A and P when D converges to 0, we defined an inequality 10 that holds true when the disease is susceptible to the prodrug (i.e., Dss = 0) (Equation S1.5). 
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Therefore, when the collective values of a, b, c, and d contradict this inequality, the disease will reach carrying capacity (Dmax), which is a state of defiance. Using this condition, we defined a dimensionless group, the General Advantage Key (GAK), which predicts the critical point at which 15 diseases switch to a state of defiance (Equation S1.6). 
Therefore, high disease growth rates (a) and drug decay (d), coupled with low drug efficacy (b) and disease activity (c), result in defiance (GAK > 0). Our simulations showed that when the initial prodrug was considered non-limiting (i.e., 0 ≫ ⁄ ), the disease switched states precisely at GAK = 0, but at limiting concentrations of P0, susceptible diseases moving slowly towards elimination survived because the prodrug resource was depleted. As the starting amount of prodrug decreased, a larger fraction of systems with GAK < 0 entered the defiant state creating phase shifted step-functions. As we decreased P0, the system entered the drug-limited regime 5 faster for larger values of ⁄ , resulting in larger phase shifts (Fig. S2B) . We extended the generalizability of this model to prodrug systems that operate under nonlinear processes and confirmed computationally that higher order models produce the same switch-like behavior centered around GAK = 0 (Fig. S2C) . These parameters are fundamental pharmacokinetic quantities, which are measured for any FDA-approved prodrug. We envision the GAK to be used 10 a guiding principle for designing prodrugs that combat antibiotic failure. 
Estimating bacterial growth rate and enzymatic activity with parameter fitting
To estimate bacterial growth rate (r) and enzymatic efficiency (kcat, Km), we used parameter fitting methods to a simplified model without a prodrug (Fig. S3A) . In this model, the prodrug is substituted with a fluorescent probe (P), which is activated with the same substrate sequence as the AMP prodrug. The concentration of cleaved fluorescent probe is monitored over time, and the 5 bacterial concentration is quantified at serial time points. We fit this data to the two equations modelling bacterial growth and activation of the fluorescent probe (Equations S1.7, 1.8). cat m dP P kB dt K P =− + (S1.8)
We found experimentally that the final bacteria population (i.e., steady-state value) was binary: 10 either 0 or Bmax. This is confirmed analytically because the steady state value of Uss is always 0, so the steady state value of B only has two possible values (Equation S1.9, 1.10). 
